论文部分内容阅读
随着基因工程技术的进展,最近 Feng 等人制成了一种奇妙的多肽——将两种类型的细胞因子,即γ-干扰素(INF-γ)和β-肿瘤坏死因子(TNF-B)合二为一的物质。TNF-β是1968年 Granger 和 Williams报道的来源于淋巴细胞具有细胞毒性的多肽。那时曾称为淋巴毒素(LT)。LT 来源于巨噬细胞的抗肿瘤多肽,它与 TNF 有相同的受体。因为它们的生物学作用基本相同,故将 LT 称为 TNF-β;将 TNF 称作 TNF-α。笔者认为,还是称它 LT 较为妥当。TNF 不仅是肿瘤坏死因子,而且尚有其它许多生物学作用,所以这种名称似不妥。经过将 LT 基因克隆化及基因重组获得了大量高纯度的物质,并与 TNF 联合试用于治疗肿瘤的临床试验。但 TNF 和 LT 在治疗肿瘤患者的过程中,并未显示那种在移植肿瘤或肿瘤细胞培养中所见的强烈抗肿瘤作用,没有取得预期的治疗效果。为了增强 TNF 和 LT 所具有的抗肿瘤作用,进行了改变它们一部分氨基
With the progress of genetic engineering technology, recently, Feng et al. have made a wonderful peptide--the two types of cytokines, IFN-γ and β-tumor necrosis factor (TNF-B). ) Combined material. TNF-[beta] is a polypeptide derived from lymphocyte cytotoxicity reported by Granger and Williams in 1968. It was known as lymphotoxin (LT) at that time. LT is derived from macrophage antitumor polypeptides, which have the same receptors as TNF. Because their biological effects are basically the same, LT is called TNF-β; TNF is called TNF-α. The author believes that it is more appropriate to call it LT. TNF is not only tumor necrosis factor, but there are many other biological effects, so this name seems inappropriate. After cloning and gene recombination of the LT gene, a large amount of high-purity substances were obtained and used together with TNF in clinical trials for treating tumors. However, TNF and LT did not show the strong anti-tumor effects seen in transplanted tumors or tumor cell cultures in the treatment of cancer patients and did not achieve the desired therapeutic effect. In order to enhance the anti-tumor effects of TNF and LT, some amino acids were changed.